Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Summit Therapeutics and Arcus Biosciences Launch Global Trial of Ivonescimab-Casdatifan Combination for Renal Cell Carcinoma

Fineline Cube Jul 23, 2026
Company Deals

Shanghai Pharmaceuticals Commits $42M to SIIC Bio-Med Fund Targeting FIC/BIC Assets from IND to Phase II

Fineline Cube Jul 22, 2026
Company Deals

TYK Medicines and Qilu Pharmaceutical Forge Strategic Partnership for EGFR-TKI TY-9591 with $2.4B Deal

Fineline Cube Jul 22, 2026
Company Deals

Trinomab Biotechnology Debuts on Shanghai STAR Market with First-in-Class Anti-Tetanus Monoclonal Antibody

Fineline Cube Jul 22, 2026
Company Deals

Grand Pharma Partners with Siemens Healthineers to Commercialize AcuNav Lumos 4D ICE Catheter in China’s Structural Heart Market

Fineline Cube Jul 21, 2026
Policy / Regulatory

Trump Announces Phased Tariff Policy on Generic Drug Imports to Incentivize U.S. Manufacturing Reshoring

Fineline Cube Jul 23, 2026
Company Drug

CSPC Pharmaceutical Launches Phase 2 Trial of SYS 6026 mRNA Vaccine for HPV-Related Cervical Precancer

Fineline Cube Jul 23, 2026
Company Drug

PegBio Launches Commercial Prescriptions for Paidakang GLP-1RA in China, Triggers Milestone Payments

Fineline Cube Jul 23, 2026
Company Drug

Pfizer’s Cibinqo and Everest Medicines’ Cefepime-Taniborbactam Selected for Priority Reviews by CDE

Fineline Cube Sep 20, 2023

The Center for Drug Evaluation (CDE) has indicated on its website that Pfizer’s (NYSE: PFE)...

Company Drug

EMA’s CHMP Supports Gilead’s Veklury for COVID-19 Patients with Hepatic Impairment

Fineline Cube Sep 20, 2023

The European Medicines Agency (EMA)’s Committee for Medicinal Products for Human Use (CHMP) has recently...

Company Deals

Eli Lilly Partners with Boundless Bio to Develop CHK1 Inhibitor for Solid Tumors

Fineline Cube Sep 20, 2023

Eli Lilly (NYSE: LLY) has announced a partnership with precision oncology specialist Boundless Bio to...

Policy / Regulatory

NHSA Clears Retagliptin and Ambroxol for National Reimbursement Drug List Inclusion

Fineline Cube Sep 20, 2023

The National Healthcare Security Administration (NHSA) has completed a review of the National Reimbursement Drug...

Company Drug

FDA Grants Priority Review to MSD’s Welireg for Advanced RCC Indication Extension

Fineline Cube Sep 20, 2023

The US Food and Drug Administration (FDA) has granted priority review status to an indication...

Company Deals

Kangtai Biological Expands Global Reach with Varicella Vaccine Licensing Deals

Fineline Cube Sep 20, 2023

Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601), a China-based biopharmaceutical company, has entered into...

Company Drug

Astellas Pharma’s Xtandi NDA for mHSPC Treatment Accepted by China’s CDE

Fineline Cube Sep 20, 2023

Japan-based Astellas Pharma Inc. (TYO: 4503) has announced that the Center for Drug Evaluation (CDE)...

Company Drug

Pfizer’s Litfulo Earns EU Approval as First Treatment for Severe Alopecia Areata in Teens

Fineline Cube Sep 20, 2023

Pfizer (NYSE: PFE) has been granted registration authorization by the European Commission (EC) for Litfulo...

Company Deals

Tianjin Century Kangtai Biomedical Raises Hundreds of Millions in Series A+ and B Financings

Fineline Cube Sep 20, 2023

Tianjin Century Kangtai Biomedical Engineering Co., Ltd, a China-based company, has reportedly secured hundreds of...

Company Drug

Walvax Biotechnology Receives Indonesian FDA Approval for Phase III Pneumococcal Vaccine Trial

Fineline Cube Sep 20, 2023

China’s Walvax Biotechnology Co., Ltd (SHE: 300142) has announced that it has received approval from...

Company Drug

Sunshine Guojian Pharmaceutical Gets NMPA Approval for SSGJ-611 Phase II COPD Study

Fineline Cube Sep 20, 2023

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, (SHA: 688336) a subsidiary of 3SBio Inc. (HKG: 1530),...

Company Drug

AbbVie’s Allergan Aesthetics Secures NMPA Approval for Juvéderm VOLUMA with Lidocaine

Fineline Cube Sep 20, 2023

Allergan Aesthetics, a subsidiary of AbbVie (NYSE: ABBV), has announced that it has received marketing...

Company Deals

Northeast Pharmaceutical Partners with Muscat Changming for Middle East Expansion

Fineline Cube Sep 20, 2023

China-based Northeast Pharmaceutical Co., Ltd (SHE: 000597) has entered into an investment framework agreement with...

Company Deals

Cure Genetics and Frametact Ltd Partner on AAV Vectors for Neurological Diseases

Fineline Cube Sep 19, 2023

Suzhou-based Cure Genetics has entered into a collaboration and licensing agreement with Hong Kong’s Frametact...

Company Drug

Caliway Biopharmaceuticals’ CBL-514 Achieves Milestones in Dercum’s Disease Trial

Fineline Cube Sep 19, 2023

Taiwan-based Caliway Biopharmaceuticals, a specialist in medical aesthetics and inflammatory medicine, has announced that its...

Company Deals

BRIM Biotechnology Raises $45.8 Million in Premium Share Issue for Pipeline Expansion

Fineline Cube Sep 19, 2023

Taiwan-based BRIM Biotechnology, Inc. (TPEx 6885), a biotechnology company specializing in the development of regenerative...

Company Deals

Suzhou Acumen Biomedical Secures $13.8 Million in Series A+ Funding Round

Fineline Cube Sep 19, 2023

China’s Suzhou Acumen Biomedical Technology Co., Ltd. has reportedly raised close to RMB 100 million...

Company Medical Device

MicroPort MedBot’s SkyWalker Robot Approved for Orthopedic Surgery by NMPA

Fineline Cube Sep 19, 2023

Shanghai MicroPort MedBot (Group) Co., Ltd (HKG: 2252) has announced that it has received marketing...

Company Drug

Zhejiang Medicine Gets NMPA Approval for NCB003 Clinical Study for Advanced Solid Tumors

Fineline Cube Sep 19, 2023

Zhejiang Medicine Co., Ltd (SHA: 600216), a China-based pharmaceutical company, has announced that it has...

Company Drug

Zelgen Biopharmaceuticals’ rhTSH Achieves Primary Endpoint in Phase III Study

Fineline Cube Sep 19, 2023

Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266), a China-based pharmaceutical company, has announced that its...

Posts pagination

1 … 503 504 505 … 699

Recent updates

  • MicroPort MedBot Achieves First-Ever Semi-Annual Profit on 200-230% Revenue Surge
  • CSPC Pharmaceutical Launches Phase 2 Trial of SYS 6026 mRNA Vaccine for HPV-Related Cervical Precancer
  • PegBio Launches Commercial Prescriptions for Paidakang GLP-1RA in China, Triggers Milestone Payments
  • Sino Biopharmaceutical Subsidiary Secures NMPA Approval for IM-101 Therapeutic Vaccine in Chronic Hepatitis B
  • OrbusNeich Enrolls First Patient in Pivotal Japanese Trial for Proprietary Drug-Coated Balloon
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Medical Device

MicroPort MedBot Achieves First-Ever Semi-Annual Profit on 200-230% Revenue Surge

Company Drug

CSPC Pharmaceutical Launches Phase 2 Trial of SYS 6026 mRNA Vaccine for HPV-Related Cervical Precancer

Company Drug

PegBio Launches Commercial Prescriptions for Paidakang GLP-1RA in China, Triggers Milestone Payments

Company Drug

Sino Biopharmaceutical Subsidiary Secures NMPA Approval for IM-101 Therapeutic Vaccine in Chronic Hepatitis B

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.